Who
Michael D. Dale
Director
Company insider
Files Form 4 as: Director, CVRx; Chief Executive Officer, Axogen; Senior Vice President, Abbott Laboratories; President and CEO, Gi Dynamics; Chief Executive Officer, Ats Medical; Director, Enpath Medical.
In numbers
- Trades disclosed
- 126
- Buys
- 0
- Sells
- 30
- Bought
- $0
- Sold
- $6.9M
- Companies
- 6
- Companies where not an officer
- 2
- First trade
- 10 Jan 2006
- Last trade
- 1 Jun 2026
- Last filed
- 3 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jun 2026filed 3 Jun 2026 | CVRX CVRxMedical Devices | SEC FORM 4 Code A | —29,005 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | CVRX CVRxoption or derivative · Medical Devices | SEC FORM 4 Code A | —36,252 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | CVRX CVRxoption or derivative · Medical Devices | SEC FORM 4 Code A | —36,252 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | CVRX CVRxMedical Devices | SEC FORM 4 Code A | —29,005 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | AXGN Axogenoption or derivative · Medical Devices | SEC FORM 4 Code A | —98,000 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | AXGN Axogenoption or derivative · Medical Devices | SEC FORM 4 Code A | —98,000 at $0.00 | filing |
| 10 Dec 2025filed 12 Dec 2025 | AXGN AxogenMedical Devices | SEC FORM 4 Sold | $750K25,000 at $30.00 | filing |
| 9 Dec 2025filed 10 Dec 2025 | AXGN AxogenMedical Devices | SEC FORM 4 Sold | $1.9M61,463 at $31.21 | filing |
| 4 Dec 2025filed 5 Dec 2025 | AXGN AxogenMedical Devices | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 25 Mar 2025filed 26 Mar 2025 | AXGN Axogenoption or derivative · Medical Devices | SEC FORM 4 Code A | —176,300 at $0.00 | filing |
| 9 Aug 2024filed 9 Aug 2024 | AXGN Axogenoption or derivative · Medical Devices | SEC FORM 4 Code A | —450,000 at $0.00 | filing |
| 1 Mar 2023filed 2 Mar 2023 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Sold | $122K1,209 at $100.70 | filing |
| 28 Feb 2023filed 2 Mar 2023 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code F | $493K4,942 at $99.77 | filing |
| 17 Feb 2023filed 22 Feb 2023 | ABT Abbott Laboratoriesoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,483 at $0.00 | filing |
| 17 Feb 2023filed 22 Feb 2023 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code A | —9,504 at $0.00 | filing |
| 8 Mar 2022filed 10 Mar 2022 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Sold | $468K4,000 at $117.00 | filing |
| 1 Mar 2022filed 2 Mar 2022 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Sold | $124K1,053 at $118.15 | filing |
| 28 Feb 2022filed 2 Mar 2022 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code F | $551K4,505 at $122.41 | filing |
| 18 Feb 2022filed 23 Feb 2022 | ABT Abbott Laboratoriesoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,280 at $0.00 | filing |
| 18 Feb 2022filed 23 Feb 2022 | ABT Abbott LaboratoriesBiotechnology | SEC FORM 4 Code A | —11,647 at $0.00 | filing |
News
Analyzing AxoGen (NASDAQ:AXGN) & AtriCure (NASDAQ:ATRC)AXGN · tickerreport.com · 18 Oct 2026
0 headlines in the last 90 days name Michael D. Dale; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.